Ajay K. Singh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ajay K. Singh has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
Bertram Pitt
3 shared publicationsGerasimos Filippatos
3 shared publicationsChristiane Ahlers
2 shared publicationsKatja Rohwedder
2 shared publicationsLuis M. Ruilope
Cardiorenal Translational Laboratory and Hypertension Unit, Institute of Research imas12, Madrid, Spain
2 shared publicationsMarc Lambelet
2 shared publications
Latest Publications
- Open Access
- 31 March 2026
- Published by S. Karger AG in American Journal of Nephrology
- p. 1-12
Effect of Finerenone Treatment Discontinuation on Kidney and Cardiovascular Outcomes: A Fidelity Analysis
Introduction: Finerenone reduced the risk of heart and kidney events in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) in FIDELITY, a prespecified pooled analysis combining data from the phase III FIDELIO-DKD (NCT02540993) and FIGARO-DKD (NCT02545049) trials. This FIDELITY analysis aimed to identify and assess key predictors of finerenone discontinuation and evaluate the impact of discontinuation on its efficacy in people with CKD and T2D. Methods: Adults with CKD (urine albumin-to-creatinine ratio 30–≤5,000 mg/g, estimated glomerular filtration rate [eGFR] ≥25 mL/min/1.73 m2) and T2D on optimized renin-angiotensin system inhibition were randomized 1:1 to finerenone or placebo. Baseline characteristics were identified and assessed as predictors of treatment discontinuation using a multivariate Cox proportional hazards model. Stratified Cox models with treatment discontinuation as a time-varying covariate were used to assess the effect of treatment discontinuation on composite kidney and cardiovascular (CV) outcomes (kidney: kidney failure, sustained ≥57% eGFR decrease from baseline over at least 4 weeks, or kidney-related death; CV: CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure). Results: Among 12,990 participants included in the analysis, 22.8% and 21.6% prematurely discontinued treatment in the finerenone and placebo arms, respectively. Advanced age, White/Black race, lower eGFR, higher urine albumin-to-creatinine ratio, and higher serum potassium at baseline were identified as predictors of finerenone discontinuation. Crude event rates per 100 patient-years for the composite kidney and CV outcomes were lower with finerenone versus placebo under treatment (kidney: 1.09 vs. 1.71; CV: 2.98 vs. 3.78) as well as after discontinuation (kidney: 11.95 vs. 13.67; CV: 14.07 vs. 14.73). The effect of finerenone on composite kidney and CV outcomes appeared to be reduced after discontinuation (hazard ratio [HR] = 0.82; 95% confidence interval [CI] 0.66–1.02; HR = 0.93; 95% CI: 0.79–1.09, respectively) versus the time on-treatment (HR = 0.65; 95% CI: 0.54–0.78; pinteraction = 0.0959; HR = 0.79; 95% CI: 0.70–0.88; pinteraction = 0.0960, respectively). Conclusion: In FIDELITY, treatment discontinuation rates were similar in the finerenone and placebo arms. Finerenone demonstrated numerically higher kidney and CV benefits during treatment versus after discontinuation.
- 31 March 2026
- Published by S. Karger AG in American Journal of Nephrology
- p. 1-12
Open AccessEffect of Finerenone Treatment Discontinuation on Kidney and Cardiovascular Outcomes: A Fidelity Analysis
Introduction: Finerenone reduced the risk of heart and kidney events in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) in FIDELITY, a prespecified pooled analysis combining data from the phase III FIDELIO-DKD (NCT02540993) and FIGARO-DKD (NCT02545049) trials. This FIDELITY analysis aimed to identify and assess key predictors of finerenone discontinuation and evaluate the impact of discontinuation on its efficacy in people with CKD and T2D. Methods: Adults with CKD (urine albumin-to-creatinine ratio 30–≤5,000 mg/g, estimated glomerular filtration rate [eGFR] ≥25 mL/min/1.73 m2) and T2D on optimized renin-angiotensin system inhibition were randomized 1:1 to finerenone or placebo. Baseline characteristics were identified and assessed as predictors of treatment discontinuation using a multivariate Cox proportional hazards model. Stratified Cox models with treatment discontinuation as a time-varying covariate were used to assess the effect of treatment discontinuation on composite kidney and cardiovascular (CV) outcomes (kidney: kidney failure, sustained ≥57% eGFR decrease from baseline over at least 4 weeks, or kidney-related death; CV: CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure). Results: Among 12,990 participants included in the analysis, 22.8% and 21.6% prematurely discontinued treatment in the finerenone and placebo arms, respectively. Advanced age, White/Black race, lower eGFR, higher urine albumin-to-creatinine ratio, and higher serum potassium at baseline were identified as predictors of finerenone discontinuation. Crude event rates per 100 patient-years for the composite kidney and CV outcomes were lower with finerenone versus placebo under treatment (kidney: 1.09 vs. 1.71; CV: 2.98 vs. 3.78) as well as after discontinuation (kidney: 11.95 vs. 13.67; CV: 14.07 vs. 14.73). The effect of finerenone on composite kidney and CV outcomes appeared to be reduced after discontinuation (hazard ratio [HR] = 0.82; 95% confidence interval [CI] 0.66–1.02; HR = 0.93; 95% CI: 0.79–1.09, respectively) versus the time on-treatment (HR = 0.65; 95% CI: 0.54–0.78; pinteraction = 0.0959; HR = 0.79; 95% CI: 0.70–0.88; pinteraction = 0.0960, respectively). Conclusion: In FIDELITY, treatment discontinuation rates were similar in the finerenone and placebo arms. Finerenone demonstrated numerically higher kidney and CV benefits during treatment versus after discontinuation.
- Open Access
- 28 November 2025
- Published by Elsevier in Kidney International Reports
- Vol. 11 (3) , 103704
A FIDELITY Analysis on Finerenone With SGLT-2i and GLP-1RA in CKD
- 28 November 2025
- Published by Elsevier in Kidney International Reports
- Vol. 11 (3) , 103704
Open AccessA FIDELITY Analysis on Finerenone With SGLT-2i and GLP-1RA in CKD
- Open Access
- 26 February 2025
- Published by Elsevier in JACC: Advances
- Vol. 4 (2) , 101524
Finerenone Efficacy in Patients with Chronic Kidney Disease, Type 2 Diabetes, and Anemia in FIDELITY
- 26 February 2025
- Published by Elsevier in JACC: Advances
- Vol. 4 (2) , 101524
Open AccessFinerenone Efficacy in Patients with Chronic Kidney Disease, Type 2 Diabetes, and Anemia in FIDELITY
- 22 April 2022
- Published by S. Karger AG in American Journal of Nephrology
- Vol. 53 (5) , 361-365
Debate: Are HIF Stabilizers a Viable Alternative to ESAs in the Management of Anemia in CKD? PRO
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
- 22 April 2022
- Published by S. Karger AG in American Journal of Nephrology
- Vol. 53 (5) , 361-365
Debate: Are HIF Stabilizers a Viable Alternative to ESAs in the Management of Anemia in CKD? PRO
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
- Open Access
- 4 April 2022
- Published by American Medical Association (AMA) in JAMA Internal Medicine
- Vol. 182 (6) , 592-602
Efficacy and Safety of Daprodustat for Treatment of Anemia of Chronic Kidney Disease in Incident Dialysis Patients
The first 90 days of initiating dialysis is a period of high risk for patients, with mortality twice as high as the mortality in the subsequent 9 months.1-3 Incident dialysis (ID) is arbitrarily defined as dialysis initiated within 90 to 120 days.1,2,4 Incident dialysis patients undergo abrupt physiological and psychological changes, including metabolic flux from clearances of uremic mediators, correction of anemia, and changes in parameters of metabolic bone disease, blood pressure, and extracellular volume.2,5 Patients also have evidence of heightened inflammation and protein-calorie malnutrition.2,5 Few studies have examined the efficacy and safety of erythropoiesis stimulating agents (ESAs) and the novel hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) during this important phase of chronic kidney disease (CKD).
- 4 April 2022
- Published by American Medical Association (AMA) in JAMA Internal Medicine
- Vol. 182 (6) , 592-602
Open AccessEfficacy and Safety of Daprodustat for Treatment of Anemia of Chronic Kidney Disease in Incident Dialysis Patients
The first 90 days of initiating dialysis is a period of high risk for patients, with mortality twice as high as the mortality in the subsequent 9 months.1-3 Incident dialysis (ID) is arbitrarily defined as dialysis initiated within 90 to 120 days.1,2,4 Incident dialysis patients undergo abrupt physiological and psychological changes, including metabolic flux from clearances of uremic mediators, correction of anemia, and changes in parameters of metabolic bone disease, blood pressure, and extracellular volume.2,5 Patients also have evidence of heightened inflammation and protein-calorie malnutrition.2,5 Few studies have examined the efficacy and safety of erythropoiesis stimulating agents (ESAs) and the novel hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) during this important phase of chronic kidney disease (CKD).
- Open Access
- 1 January 2020
- Published by Taylor & Francis in Renal Failure
- Vol. 42 (1) , 1032-1041
Occupational risk factors for chronic kidney disease in Andhra Pradesh: ‘Uddanam Nephropathy’
CKD of unknown etiology (CKDu) has been reported in several countries including India. We previously showed a prevalence of CKD in India to be 17.2% and we found a CKD epidemic in Andhra Pradesh (A...
- 1 January 2020
- Published by Taylor & Francis in Renal Failure
- Vol. 42 (1) , 1032-1041
Open AccessOccupational risk factors for chronic kidney disease in Andhra Pradesh: ‘Uddanam Nephropathy’
CKD of unknown etiology (CKDu) has been reported in several countries including India. We previously showed a prevalence of CKD in India to be 17.2% and we found a CKD epidemic in Andhra Pradesh (A...
- Top Cited PapersOpen Access
- 3 January 2017
- Published by Springer Nature in BMC Nephrology
- Vol. 18 (1) , 1-8
International Collaboration for the Epidemiology of eGFR in Low and Middle Income Populations - Rationale and core protocol for the Disadvantaged Populations eGFR Epidemiology Study (DEGREE)
There is an increasing recognition of epidemics of primarily tubular-interstitial chronic kidney disease (CKD) clustering in agricultural communities in low- and middle-income countries (LMICs). Although it is currently unclear whether there is a unified underlying aetiology, these conditions have been collectively termed CKD of undetermined cause (CKDu). CKDu is estimated to have led to the premature deaths of tens to hundreds of thousands of young men and women over the last 2 decades. Thus, there is an urgent need to understand the aetiology and pathophysiology of these condition (s). International comparisons have provided the first steps in understanding many chronic diseases, but such comparisons rely on the availability of standardised tools to estimate disease prevalence. This is a particular problem with CKD, since the disease is asymptomatic until the late stages, and the biases inherent in the methods used to estimate the glomerular filtration rate (GFR) in population studies are highly variable across populations. We therefore propose a simple standardised protocol to estimate the distribution of GFR in LMIC populations – The Disadvantaged Populations eGFR Epidemiology (DEGREE) Study. This involves the quantification of renal function in a representative adult population-based sample and a requirement for standardisation of serum creatinine measurements, along with storage of samples for future measurements of cystatin C and ascertainment of estimates of body composition, in order to obtain valid comparisons of estimated GFR (eGFR) within and between populations. The methodology we present is potentially applicable anywhere, but our particular focus is on disadvantaged populations in LMICs, since these appear to be most susceptible to CKDu. Although the protocol could also be used in specific groups (e.g. occupational groups, thought to be at excess risk of CKDu) the primary aim of the DEGREE project is characterise the population distribution of eGFR in multiple regions so that international comparisons can be performed. It is only with a standardised approach that it will be possible to estimate the scale of, and variation in, impaired kidney function between affected areas. These data should then provide insights into important social, demographic and environmental risk factors for this increasingly recognised disease.
- 3 January 2017
- Published by Springer Nature in BMC Nephrology
- Vol. 18 (1) , 1-8
Top Cited PapersOpen AccessInternational Collaboration for the Epidemiology of eGFR in Low and Middle Income Populations - Rationale and core protocol for the Disadvantaged Populations eGFR Epidemiology Study (DEGREE)
There is an increasing recognition of epidemics of primarily tubular-interstitial chronic kidney disease (CKD) clustering in agricultural communities in low- and middle-income countries (LMICs). Although it is currently unclear whether there is a unified underlying aetiology, these conditions have been collectively termed CKD of undetermined cause (CKDu). CKDu is estimated to have led to the premature deaths of tens to hundreds of thousands of young men and women over the last 2 decades. Thus, there is an urgent need to understand the aetiology and pathophysiology of these condition (s). International comparisons have provided the first steps in understanding many chronic diseases, but such comparisons rely on the availability of standardised tools to estimate disease prevalence. This is a particular problem with CKD, since the disease is asymptomatic until the late stages, and the biases inherent in the methods used to estimate the glomerular filtration rate (GFR) in population studies are highly variable across populations. We therefore propose a simple standardised protocol to estimate the distribution of GFR in LMIC populations – The Disadvantaged Populations eGFR Epidemiology (DEGREE) Study. This involves the quantification of renal function in a representative adult population-based sample and a requirement for standardisation of serum creatinine measurements, along with storage of samples for future measurements of cystatin C and ascertainment of estimates of body composition, in order to obtain valid comparisons of estimated GFR (eGFR) within and between populations. The methodology we present is potentially applicable anywhere, but our particular focus is on disadvantaged populations in LMICs, since these appear to be most susceptible to CKDu. Although the protocol could also be used in specific groups (e.g. occupational groups, thought to be at excess risk of CKDu) the primary aim of the DEGREE project is characterise the population distribution of eGFR in multiple regions so that international comparisons can be performed. It is only with a standardised approach that it will be possible to estimate the scale of, and variation in, impaired kidney function between affected areas. These data should then provide insights into important social, demographic and environmental risk factors for this increasingly recognised disease.
- 14 June 2016
- Published by Springer Nature
- p. 93-102
Managing Anemia and Metabolic Bone Disease in Dialysis Patients
- 14 June 2016
- Published by Springer Nature
- p. 93-102
Managing Anemia and Metabolic Bone Disease in Dialysis Patients